BridgeBio Pharma, Inc.
encaleret
autosomal dominant hypocalcemia type 1 (ADH1)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on encaleret for autosomal dominant hypocalcemia type 1 (ADH1) is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Phase 3 study to be initiated in 2H 2026”